Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Pharsight Q4 and Year-over-Year Revenue Up

SAN FRANCISCO, April 30 - Pharsight today reported increased quarterly and year-over-year revenue.

 

Total revenue for the fiscal year ended March 31, 2002increased to $14.2 million compared to $11.9 million for the previous year.

 

Total revenue for the quarter ended March 31 were $3.8 million compared with $3 million in the year-ago period. The net loss for the quarter dropped to $3.4 million, or $.18 per share, from $6 million, or $.33 a share, for the same period a year ago.

R&D for the fiscal year dropped to $6.6 million from $8.1 million in the previous year. R&D spending was cut back to $1.5 million in the fourth quarter from $2.3 million for the year-ago period. 

 

Pharsight revised its projection of EBITDA breakeven for the end of June 2003 from previously announced end of calendar year 2002.

 

The company said it had $13.6 million in cash, cash equivalents, and short-term investments as of March 31.

 

For more information, click here.

 

Pharsight also said today that it signed Aventis Pharma to a software and support deal, its largest customer deal to date, according to the company.

 

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.